Objectives / Review Questions
1. Which chronodisruption exposures have been studied in adults undergoing MBS?
2. How have these exposures been measured (e.g., PSQI, actigraphy, MEQ, social jetlag computation, meal-timing thresholds, shift-work status, LAN measures)?
3. What postoperative weight outcomes have been reported, and what is the direction/consistency of associations?
Population–Concept–Context (PCC)
- Population: Adults (≥18 years) undergoing MBS (e.g., RYGB, SG, OAGB).
- Concept: Chronodisruption exposures: sleep duration/quality/timing; chronotype; SJL; meal timing/chrononutrition; shift work; LAN.
- Context: Associations with postoperative weight outcomes (%EWL, %TWL, BMI change, insufficient weight loss, WR/RWG).
- Adult bariatric/metabolic surgery cohorts or comparative studies.
- At least one chronodisruption exposure measured (e.g., Pittsburgh Sleep Quality Index [PSQI], actigraphy, Morningness–Eveningness Questionnaire [MEQ], computed SJL, explicit meal-timing thresholds such as “main meal before vs after 15:00”, shift-work status, LAN by self-report or objective light).
- At least one postoperative weight outcome: %EWL, %TWL, BMI change, insufficient weight loss, or WR/RWG.
- Any country, setting, or surgery type.
- Pediatric cohorts; non-bariatric samples.
- Studies reporting only pre/post sleep or obstructive sleep apnoea (OSA) changes without relating a chronodisruption exposure to weight outcomes.
- Editorials, commentaries, and case reports.
- Genetics-only analyses (e.g., CLOCK variants) unless a behavioral chronodisruption exposure is also modeled.
- Non-human experiments (retained separately as mechanistic context; not synthesized with human outcomes).
Study Records and Workflow
- Search 6 screening: AGP, VT (independent).
- Data charting: AGP, ZP (independent).
- Adjudication: DPL (referee).
4. Title/abstract screening against eligibility criteria.
5. Full-text assessment for potentially eligible records.
6. Cohort de-duplication: when multiple reports use the same cohort, retain the most comprehensive/longest-follow-up analysis; cite companions narratively.
We will chart data using a piloted form with the fields below. A short calibration exercise on 3–5 papers will harmonize coding before charting the full sample.
| Category | Author | Year | Reference (journal; year; vol(issue):pages) | Design | n | Exposure | Outcome | Key findings |
|---|---|---|---|---|---|---|---|---|
| Sleep timing / Chronotype / SJL / Meal timing / Shift work / LAN | Surname Initials | Year | Journal; Year; Volume (Issue): Pages | Prospective cohort / Retrospective / Cross-sectional | n | Instrument/definition (e.g., PSQI, actigraphy, MEQ, SJL calc, meal-time threshold, shift-work, LAN) | Weight metric 6 timepoint (%EWL, %TWL, BMI; WRG) | ≤2–3 lines; direction/consistency |
Formal risk-of-bias assessment is not required for scoping reviews. For clinical interpretability, we will provide a concise Newcastle–Ottawa Scale (NOS)–style summary for cohort/retrospective designs and an adapted read-across for cross-sectional studies. Quality appraisal will not be used as an exclusion criterion.
We will provide a descriptive mapping by chronodisruption domain (sleep duration/quality/timing; chronotype; SJL; meal timing/chrononutrition; shift work; LAN), summarizing measurement approaches, surgery types, weight outcomes, and directions of association. No meta-analysis will be conducted. Results will include a PRISMA-ScR flow diagram, the evidence table (with the charted fields above), and a narrative summary of gaps and priorities (e.g., objective exposure assessment, standardized WRG definitions, longer follow-up).
Outcomes and Prioritization
Where multiple weight metrics are reported, we will preferentially chart percent excess weight loss (%EWL) or percent total weight loss (%TWL) near 12 months and the longest available follow-up thereafter. WR/RWG definitions will be recorded verbatim.
Any protocol amendments (scope, sources, eligibility) will be time-stamped in Protocols.io and reflected in the final manuscript (Methods and Supplement).